Sanofi Rises 2 Positions in the 2016 Access to Medicine Index
In 2016, Sanofi has risen 2 positions in the Access To Medicine (ATM) Index, from 8th to 6th rank. The ATM Index analyses the top 20 research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries.
Sanofi’s performance is well recognized this year in the two main areas, which represent 45% of the overall score and are major enablers of access:
Research & Development:
Our performance in R&D is due to a larger relevant pipeline with 28 relevant R&D projects, including several new fixed-dose combinations for treating tuberculosis and a paediatric formulation of primaquine for malaria, to high standards of transparency regarding our clinical trial data and to the sharing of intellectual property with several partners in order to accelerate research in tuberculosis, malaria and neglected tropical diseases.
Pricing, Manufacturing & Distribution:
Sanofi improved in equitable pricing. We are among the 3 companies having the best performance to meet the key criteria set by the Index for pricing strategies. Besides, we are the company leader marketing the most essential medicines and vaccines (WHO Model Essential Medicines List).
The ATM Index also recognizes our innovative approach in the field of “climate change and health” still confirmed these days with our participation to COP22 at Marrakech. For more than 2 years now, we have been investigating health- and access-related issues linked to climate change.
Finally, Sanofi is the biggest riser in the area of marketing practices and compliance, climbing 13 places into the top 5. The ATM index notably emphasizes our above-average transparency and our certification system that allows us to regularly test and update the skills of our sales agents.
